{"id":"https://openalex.org/W4382631334","doi":"https://doi.org/10.1093/jpids/piad031","title":"Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)","display_name":"Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4382631334","doi":"https://doi.org/10.1093/jpids/piad031","pmid":"https://pubmed.ncbi.nlm.nih.gov/37389891","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10312293"},"language":"en","primary_location":{"id":"doi:10.1093/jpids/piad031","doi":"https://doi.org/10.1093/jpids/piad031","is_oa":true,"landing_page_url":"https://doi.org/10.1093/jpids/piad031","pdf_url":"https://academic.oup.com/jpids/article-pdf/12/6/334/50764959/piad031.pdf","source":{"id":"https://openalex.org/S2912147776","display_name":"Journal of the Pediatric Infectious Diseases Society","issn_l":"2048-7193","issn":["2048-7193","2048-7207"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the Pediatric Infectious Diseases Society","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://academic.oup.com/jpids/article-pdf/12/6/334/50764959/piad031.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080838490","display_name":"Thomas J. Sferra","orcid":"https://orcid.org/0000-0001-6893-9880","observed_orcids":["https://orcid.org/0000-0001-6893-9880"]},"institutions":[{"id":"https://openalex.org/I4210151235","display_name":"Rainbow Babies & Children's Hospital","ror":"https://ror.org/04x495f64","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799343972","https://openalex.org/I4210151235"]},{"id":"https://openalex.org/I58956616","display_name":"Case Western Reserve University","ror":"https://ror.org/051fd9666","country_code":"US","type":"education","lineage":["https://openalex.org/I58956616"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas J Sferra","raw_affiliation_strings":["Department of Pediatrics, UH Rainbow Babies & Children\u2019s Hospital and Case Western Reserve University School of Medicine , Cleveland, Ohio , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatrics, UH Rainbow Babies & Children\u2019s Hospital and Case Western Reserve University School of Medicine , Cleveland, Ohio , USA","institution_ids":["https://openalex.org/I4210151235","https://openalex.org/I58956616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075777949","display_name":"Tom\u00e1\u0161 Merta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102302","display_name":"University Hospital Brno","ror":"https://ror.org/00qq1fp34","country_code":"CZ","type":"healthcare","lineage":["https://openalex.org/I4210102302"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Tomas Merta","raw_affiliation_strings":["Department of Pediatric Oncology, University Hospital Brno , Brno , Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatric Oncology, University Hospital Brno , Brno , Czech Republic","institution_ids":["https://openalex.org/I4210102302"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026635936","display_name":"Michael Noel Neely","orcid":"https://orcid.org/0000-0002-1675-8276","observed_orcids":["https://orcid.org/0000-0002-1675-8276"]},"institutions":[{"id":"https://openalex.org/I1336910626","display_name":"Children's Hospital Los Angeles","ror":"https://ror.org/00412ts95","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336910626"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Neely","raw_affiliation_strings":["Division of Infectious Diseases, Children\u2019s Hospital Los Angeles , Los Angeles, California , USA"],"raw_orcid":"https://orcid.org/0000-0002-1675-8276","affiliations":[{"raw_affiliation_string":"Division of Infectious Diseases, Children\u2019s Hospital Los Angeles , Los Angeles, California , USA","institution_ids":["https://openalex.org/I1336910626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086890870","display_name":"Cl\u00e1udia Murta de Oliveira","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210123796","display_name":"Grupo Santa Casa de Belo Horizonte","ror":"https://ror.org/024w2fr05","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210123796"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Claudia Murta de Oliveira","raw_affiliation_strings":["Santa Casa de Miseric\u00f3rdia , Belo Horizonte , Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Santa Casa de Miseric\u00f3rdia , Belo Horizonte , Brazil","institution_ids":["https://openalex.org/I4210123796"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029328183","display_name":"\u00c1lvaro Lassaletta","orcid":"https://orcid.org/0000-0003-2881-1473","observed_orcids":["https://orcid.org/0000-0003-2881-1473"]},"institutions":[{"id":"https://openalex.org/I4210111810","display_name":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas","ror":"https://ror.org/028brk668","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210111810","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Alvaro Lassaletta","raw_affiliation_strings":["Pediatric Hematology-Oncology Department, Hospital Ni\u00f1o Jesus , Madrid , Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pediatric Hematology-Oncology Department, Hospital Ni\u00f1o Jesus , Madrid , Spain","institution_ids":["https://openalex.org/I4210111810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010007837","display_name":"Cl\u00e0udia Fortuny Guasch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087189","display_name":"MSD (UK) Limited (United Kingdom)","ror":"https://ror.org/004nn4n27","country_code":"GB","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210087189"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Claudia Fortuny Guasch","raw_affiliation_strings":["Princeton , NJ , USA","Certara USA, Princeton, NJ, USA","Clinical Research, MSD UK, 2 Pancras Square, King's Cross, London N1C 4AG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Princeton , NJ , USA","institution_ids":[]},{"raw_affiliation_string":"Certara USA, Princeton, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Clinical Research, MSD UK, 2 Pancras Square, King's Cross, London N1C 4AG, UK","institution_ids":["https://openalex.org/I4210087189"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mary Beth Dorr","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Beth Dorr","raw_affiliation_strings":["PPDM QP2, Merck & Co., Inc. , Rahway, New Jersey , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PPDM QP2, Merck & Co., Inc. , Rahway, New Jersey , USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070756038","display_name":"Gregory A. Winchell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory Winchell","raw_affiliation_strings":["Biostatistics, Merck & Co., Inc. , Rahway, New Jersey , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, Merck & Co., Inc. , Rahway, New Jersey , USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000568465","display_name":"Feng-Hsiu Su","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Feng-Hsiu Su","raw_affiliation_strings":["Clinical Operations, Merck & Co., Inc. , Rahway, New Jersey , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Operations, Merck & Co., Inc. , Rahway, New Jersey , USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092363925","display_name":"Sarah Perko","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087189","display_name":"MSD (UK) Limited (United Kingdom)","ror":"https://ror.org/004nn4n27","country_code":"GB","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210087189"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sarah Perko","raw_affiliation_strings":["Clinical Research, MSD UK , London , UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research, MSD UK , London , UK","institution_ids":["https://openalex.org/I4210087189"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085304308","display_name":"Doreen A. Fernsler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087189","display_name":"MSD (UK) Limited (United Kingdom)","ror":"https://ror.org/004nn4n27","country_code":"GB","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210087189"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Doreen Fernsler","raw_affiliation_strings":["Clinical Research, MSD UK , London , UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research, MSD UK , London , UK","institution_ids":["https://openalex.org/I4210087189"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008561024","display_name":"Hetty A. Waskin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hetty Waskin","raw_affiliation_strings":["PPDM QP2, Merck & Co., Inc. , Rahway, New Jersey , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PPDM QP2, Merck & Co., Inc. , Rahway, New Jersey , USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5114062737","display_name":"Stephen R Holden","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087189","display_name":"MSD (UK) Limited (United Kingdom)","ror":"https://ror.org/004nn4n27","country_code":"GB","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210087189"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Stephen R Holden","raw_affiliation_strings":["Clinical Research, MSD UK , London , UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research, MSD UK , London , UK","institution_ids":["https://openalex.org/I4210087189"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5114062737"],"corresponding_institution_ids":["https://openalex.org/I4210087189"],"apc_list":{"value":4310,"currency":"USD","value_usd":4310},"apc_paid":{"value":4310,"currency":"USD","value_usd":4310},"fwci":2.4686,"has_fulltext":true,"cited_by_count":12,"citation_normalized_percentile":{"value":0.88884696,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":98},"biblio":{"volume":"12","issue":"6","first_page":"334","last_page":"341"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11288","display_name":"Clostridium difficile and Clostridium perfringens research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11288","display_name":"Clostridium difficile and Clostridium perfringens research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bezlotoxumab","display_name":"bezlotoxumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/clostridium-difficile-infection","display_name":"Clostridium difficile infection","score":0.9980000257492065},{"id":"https://openalex.org/keywords/pediatric-patients","display_name":"pediatric patients","score":0.9380000233650208},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8700000047683716},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9919999837875366},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.7310000061988831},{"id":"https://openalex.org/keywords/antibiotic-therapy","display_name":"antibiotic therapy","score":0.7459999918937683},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7990000247955322},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5830000042915344},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.3970000147819519},{"id":"https://openalex.org/keywords/age-stratified-analysis","display_name":"age-stratified analysis","score":0.4259999990463257}],"concepts":[{"id":"https://openalex.org/C2910067853","wikidata":"https://www.wikidata.org/wiki/Q27438828","display_name":"Clostridioides","level":2,"score":0.9591234922409058},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9330959320068359},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5892894268035889},{"id":"https://openalex.org/C2991744798","wikidata":"https://www.wikidata.org/wiki/Q608510","display_name":"Double blind","level":4,"score":0.5268063545227051},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3952476978302002},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.10999831557273865},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.08418723940849304}],"mesh":[{"descriptor_ui":"D000080908","descriptor_name":"Broadly Neutralizing Antibodies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003015","descriptor_name":"Clostridium Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1093/jpids/piad031","doi":"https://doi.org/10.1093/jpids/piad031","is_oa":true,"landing_page_url":"https://doi.org/10.1093/jpids/piad031","pdf_url":"https://academic.oup.com/jpids/article-pdf/12/6/334/50764959/piad031.pdf","source":{"id":"https://openalex.org/S2912147776","display_name":"Journal of the Pediatric Infectious Diseases Society","issn_l":"2048-7193","issn":["2048-7193","2048-7207"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the Pediatric Infectious Diseases Society","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10312293","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10312293","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10312293/pdf/piad031.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Pediatric Infect Dis Soc","raw_type":"Text"},{"id":"pmid:37389891","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37389891","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the Pediatric Infectious Diseases Society","raw_type":"Randomized Controlled Trial"}],"best_oa_location":{"id":"doi:10.1093/jpids/piad031","doi":"https://doi.org/10.1093/jpids/piad031","is_oa":true,"landing_page_url":"https://doi.org/10.1093/jpids/piad031","pdf_url":"https://academic.oup.com/jpids/article-pdf/12/6/334/50764959/piad031.pdf","source":{"id":"https://openalex.org/S2912147776","display_name":"Journal of the Pediatric Infectious Diseases Society","issn_l":"2048-7193","issn":["2048-7193","2048-7207"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the Pediatric Infectious Diseases Society","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8299999833106995}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320332932","display_name":"Merck Sharp and Dohme","ror":"https://ror.org/004nn4n27"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4382631334.pdf","grobid_xml":"https://content.openalex.org/works/W4382631334.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1607201706","https://openalex.org/W1974447528","https://openalex.org/W1977795613","https://openalex.org/W1994402702","https://openalex.org/W2019740102","https://openalex.org/W2034676061","https://openalex.org/W2053351082","https://openalex.org/W2060437411","https://openalex.org/W2060901588","https://openalex.org/W2102459023","https://openalex.org/W2109753600","https://openalex.org/W2122633654","https://openalex.org/W2153045087","https://openalex.org/W2163423623","https://openalex.org/W2526811413","https://openalex.org/W2537576907","https://openalex.org/W2560905656","https://openalex.org/W2582069104","https://openalex.org/W2795360200","https://openalex.org/W2901915924","https://openalex.org/W2937005171","https://openalex.org/W2990355599","https://openalex.org/W3171461532","https://openalex.org/W3211569408","https://openalex.org/W4281754969","https://openalex.org/W4293162938"],"related_works":["https://openalex.org/W4366603145","https://openalex.org/W2921610959","https://openalex.org/W2611907043","https://openalex.org/W2792120288","https://openalex.org/W2554907049","https://openalex.org/W2804220729","https://openalex.org/W2554903289","https://openalex.org/W3208721718","https://openalex.org/W2753588094","https://openalex.org/W4412116380"],"abstract_inverted_index":{"BACKGROUND:":[0],"Therapies":[1],"to":[2,57,69,90,96,103,107,216,223],"prevent":[3],"recurrence":[4,227],"of":[5,25,38,52,74,140,171,241,248],"Clostridioides":[6],"difficile":[7],"infection":[8],"(CDI)":[9],"in":[10,28,40,54],"pediatric":[11,41,112,252],"patients":[12],"are":[13],"needed.":[14],"Bezlotoxumab":[15,204],"is":[16],"a":[17,47,71],"fully":[18],"human":[19],"monoclonal":[20],"antibody":[21],"approved":[22],"for":[23,63,111,133,184,198,232,251],"prevention":[24],"recurrent":[26],"CDI":[27,226],"adults.":[29],"We":[30],"assessed":[31],"the":[32,114,118,121,245],"pharmacokinetics,":[33],"safety,":[34],"tolerability,":[35,128],"and":[36,80,129,145,152,175,191,201,230,235],"efficacy":[37,130],"bezlotoxumab":[39,53,75,105,122,151,185,233,246],"patients.":[42,253],"METHODS:":[43],"MODIFY":[44],"III":[45],"was":[46,102,117,207,228],"multicenter,":[48],"double-blind,":[49],"placebo-controlled":[50],"study":[51,243],"children":[55],"(1":[56],"<18":[58,91],"years)":[59],"receiving":[60],"antibacterial":[61],"treatment":[62,220],"CDI.":[64],"Participants":[65],"were":[66,81,131,143,147,173,177,187],"randomized":[67,144],"3:1":[68],"receive":[70],"single":[72],"infusion":[73],"(10":[76],"mg/kg)":[77],"or":[78],"placebo":[79,155,236],"stratified":[82],"by":[83],"age":[84,167],"at":[85,257],"randomization":[86],"(cohort":[87,156],"1:":[88],"12":[89,134],"years,":[92],"cohort":[93,161],"2:":[94],"1":[95,157,200],"<12":[97],"years).":[98],"The":[99,239],"primary":[100,115],"objective":[101],"characterize":[104],"pharmacokinetics":[106],"support":[108,244],"dose":[109,247],"selection":[110],"patients;":[113],"endpoint":[116],"area":[119],"under":[120],"serum":[123],"concentration-time":[124],"curve":[125],"(AUC0-inf).":[126],"Safety,":[127],"monitored":[132],"weeks":[135],"post-infusion.":[136],"RESULTS:":[137],"A":[138],"total":[139],"148":[141],"participants":[142,172],"143":[146],"treated:":[148],"107":[149],"with":[150,154,210],"36":[153],"n":[158,163],"=":[159,164],"60,":[160],"2":[162],"83;":[165],"median":[166],"9.0":[168],"years);":[169],"52.4%":[170],"male":[174],"80.4%":[176],"white.":[178],"Geometric":[179],"mean":[180],"ratios":[181],"(90%":[182],"CI)":[183],"AUC0-inf":[186],"1.06":[188],"(0.95,":[189],"1.18)":[190],"0.82":[192],"(0.75,":[193],"0.89)":[194],"h":[195],"*":[196],"\u03bcg/mL":[197],"cohorts":[199],"2,":[202],"respectively.":[203],"10":[205,249],"mg/kg":[206,250],"generally":[208],"well-tolerated":[209],"an":[211],"adverse":[212,224],"event":[213],"profile":[214],"similar":[215],"placebo,":[217],"including":[218],"no":[219],"discontinuations":[221],"due":[222],"events.":[225],"low":[229],"comparable":[231],"(11.2%)":[234],"(14.7%).":[237],"CONCLUSIONS:":[238],"results":[240],"this":[242],"TRIAL":[254],"REGISTRATION:":[255],"NCT03182907":[256],"ClinicalTrials.gov.":[258]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-07-01T00:00:00"}